Tirzepatide Shows Superior Protective Effects in Rat Model of Polycystic Ovary Syndrome
Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin.
Study Design
Population
Female Sprague-Dawley rats (n=40) with DHEA-induced polycystic ovary syndrome.
Intervention
Tirzepatide (100 nmol/kg) administered subcutaneously once daily for 21 days.
Comparator
Vehicle control (saline) administered subcutaneously once daily for 21 days.
Outcome
Changes in ovarian morphology, hormone levels (testosterone, estradiol, LH, FSH), and metabolic parameters (glucose, insulin, body weight).
Abstract
Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin.
Authors: Olewi NZ, Hassan AF
Journal: Naunyn-Schmiedeberg's archives of pharmacology…